Glioblastoma (IDH-WT, WHO grade 4)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-GBM |
|---|---|
| Type | Disease |
| Aliases | GBMGlioblastomaGlioblastoma multiforme (legacy term)Гліобластома (IDH-WT, WHO grade 4) |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9440/3 |
|---|---|
| icd_o_3_topography | ["C71"] |
| icd_10 | C71 |
| who_classification | WHO CNS Tumours 5th ed (2021): Glioblastoma, IDH-wildtype, grade 4 (the IDH-mutant grade-4 astrocytoma is a distinct entity) |
Notes
Scaffolded for batch #2: 4 RFs (intracranial-pressure emergency, MGMT-actionability, frailty/age — elderly Stupp-modified, biopsy-only vs maximal-safe-resection MDT-trigger). 1 regimen (TMZ Stupp concurrent + adjuvant). 2 indications (Stupp full for fit; TMZ-only for elderly unmethylated unfit). 1 algorithm. Lineage value `carcinoma` is suboptimal — neuroepithelial would be more accurate. Schema's lineage field is free-text Optional; using `carcinoma` for now to match other solid-tumor entries; clinical authors may want to add `glioma` / `neuroepithelial` enum value in future. RT 60 Gy / 30 fractions concurrent with TMZ 75 mg/m²/d daily during RT is the canonical Stupp concurrent phase. RT NOT modellable per PROPOSAL §17 — treated as free-text in Indication.notes for now.
Used By
Actionability
BMA-BRAF-V600E-GBM- BRAF V600E in adult-type glioblastoma is rare (~1-3%) but more common in epithelioid GBM...BMA-EGFR-MUTATION-GBM- EGFR amplification (~40%) and EGFRvIII variant (~25%) are common in glioblastoma but no t...BMA-IDH1-R132C-GBM- IDH1 R132C in glioma — non-canonical; same therapeutic implications as R132H (vorasidenib...BMA-IDH1-R132G-GBM- IDH1 R132G — covered by IDH-mut glioma vorasidenib label.BMA-IDH1-R132H-GBM- IDH1 R132H — defines IDH-mutant astrocytoma (WHO 2021 grade 2-4) and oligodendroglioma (w...BMA-IDH1-R132L-GBM- IDH1 R132L — covered by vorasidenib.BMA-IDH1-R132S-GBM- IDH1 R132S — covered by vorasidenib.BMA-MGMT-METHYLATION-GBM- MGMT promoter methylation in IDH-WT glioblastoma is the strongest validated predictor of...BMA-SUFU-GERMLINE-MEDULLOBLASTOMA- SUFU germline pathogenic variants cause a Gorlin-syndrome–like predisposition with much h...BMA-TERT-GLIOMA- TERT promoter mutations are central to WHO CNS tumor classification (2021 5th edition): (...BMA-TP53-MUT-GBM- TP53 mutation in GBM — common, adverse prognostic; not directly targeted. Per usual algor...
Algorithms
ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-GBM-NEWLY-DIAGNOSED-1L- ALGO-GBM-NEWLY-DIAGNOSED-1LALGO-GBM-RECURRENT- ALGO-GBM-RECURRENT
Disease
DIS-GLIOMA-LOW-GRADE- Low-grade glioma (LGG, WHO grade 2 — IDH-mutant)
Indication
IND-GBM-NEWLY-DIAGNOSED-ELDERLY-HYPORT- IND-GBM-NEWLY-DIAGNOSED-ELDERLY-HYPORTIND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZ- IND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZIND-GBM-NEWLY-DIAGNOSED-STUPP- IND-GBM-NEWLY-DIAGNOSED-STUPPIND-GBM-RECURRENT-BEVACIZUMAB- IND-GBM-RECURRENT-BEVACIZUMABIND-IATROGENIC-CRANIAL-RT-LATE-PREVENTION-OBSERVATION- IND-IATROGENIC-CRANIAL-RT-LATE-PREVENTION-OBSERVATIONIND-IATROGENIC-CRANIAL-RT-LATE-PREVENTION-SURVEILLANCE- IND-IATROGENIC-CRANIAL-RT-LATE-PREVENTION-SURVEILLANCE
Questionnaires
QUEST-GBM-1L-STUB- Glioblastoma — first line
Red flag
RF-CASCADE-LFS-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-GBM-FRAILTY-AGE- Frailty profile precluding standard 6-week TMZ chemoradiation in glioblastoma: KPS <70, E...RF-GBM-HIGH-RISK-BIOLOGY- Glioblastoma with adverse molecular biology under WHO CNS5 classification: MGMT promoter...RF-GBM-INFECTION-SCREENING- Active or unmanaged infection requiring resolution before initiating temozolomide (TMZ) c...RF-GBM-INTRACRANIAL-PRESSURE-EMERGENCY- Symptomatic raised intracranial pressure / mass effect in glioblastoma: declining GCS, ne...RF-GBM-TRANSFORMATION-PROGRESSION- Glioblastoma progression on or after first-line Stupp regimen: MRI evidence of true progr...RF-GLIOMA-LOW-GRADE-HIGH-RISK-BIOLOGY- Low-grade glioma with high-risk molecular features: IDH-wildtype (per WHO 5th ed., reclas...RF-IATROGENIC-CRANIAL-RT-LATE-PREVENTION- Cancer survivor ≥5 years post-completion of curative-intent oncology treatment that inclu...RF-LI-FRAUMENI-FAMILY-HISTORY-SUSPICION- Family pedigree or personal history meeting criteria suggestive of Li-Fraumeni Syndrome (...
Sources
SRC-CCTG-CE6-PERRY-2017- Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaSRC-EANO-GBM-2024- EANO Guidelines on Diagnosis and Treatment of Diffuse Gliomas of AdulthoodSRC-EF14-STUPP-2015- Maintenance Therapy with Tumor-Treating Fields plus Temozolomide vs Temozolomide Alone fo...SRC-NCCN-CNS-2025- NCCN Central Nervous System CancersSRC-NORDIC-GBM-MALMSTROM-2012- Temozolomide versus Standard 6-Week Radiotherapy versus Hypofractionated Radiotherapy in...